Trebananib: An alternative anti-angiogenic strategy

The Lancet Oncology

Volumn 15, Issue 8, 2014, Pages 776-777

  Gourley, Charlie ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; BEVACIZUMAB; DOXORUBICIN; PACLITAXEL; TOPOTECAN; TREBANANIB;

DRUG EFFICACY; DRUG SAFETY; HUMAN; NOTE; OVARY CARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BINDING; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RECOMBINANT FUSION PROTEINS;

EID: 84903540732     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70283-9     Document Type: Note

References (10)

1. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011, 365:2473-2483.
2. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011, 365:2484-2496.
3. Du Bois A, Kristensen G, Ray-Coquard I, et al. A randomized placebo-controlled GCIG/ENGOT-intergroup phase III trial of standard frontline chemotherapy +/- nintedanib for advanced ovarian cancer. Int J Gyn Cancer 2013, 23(suppl 1). LBA1 (abstr).
4. Du Bois A, Floquet A, Kim JW, et al. Randomised, double-blind phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube or promary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16). Proc Am Soc Clin Oncol 2013, 31(supp). LBA5503 (abstr).
5. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012, 30:2039-2045.
6. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 2014, 32:1302-1308.
7. Ledermann JA, Perren TJ, Raja FA, et al. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial. Eur J Cancer 2013, 49. LBA 10 (abstr).
8. Monk BJ, Poveda A, Vergote I, et al. Antiangiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014, published online June 18. http://dx.doi.org/10.1016/S1470-2045(14)70244-X.
9. Gourley C, McCavigan A, Perren T, et al. Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. Proc Am Soc Clin Oncol 2014, 32:5502. (abstr).
10. Winterhoff BJN, Kommoss S, Oberg AL, et al. Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer. Proc Am Soc Clin Oncol 2014, 32:5509. (abstr).